Bruker introduces analytical and automation innovations at analytica 2026

Bruker empowers scientists and engineers to make post-genomic discoveries and develop impactful applications. Its high-performance instruments and diagnostic solutions help advance research at the molecular, cellular, and microscopic levels. 

Bruker has presented new analytical and laboratory automation systems with products aimed at biopharma, applied research, industrial quality control, and academic laboratories. This launch includes tools for nanoparticle analysis, benchtop NMR, surface plasmon resonance, and lab workflow digitalisation. 

According to Towards Healthcare, the Pre-Analytical Automation Market is projected to experience significant growth, with estimates suggesting the market size will increase from USD 6.32 billion in 2026 to approximately USD 13.61 billion by 2035, representing a compound annual growth rate (CAGR) of 8.9% from 2026 to 2035. Growth is driven by the increasing demand for laboratory automation, resting test volume in clinical diagnostics, and the need for faster turnaround time. 

Bruker unveils iNTApharma for cell and gene therapy workflows. 

Biopharma launches the iNTApharma system, a label-free platform for quantitative characterisation of nanoscale bioparticles in aqueous media. This instrument is designed for particles in the 50 to 300 nanometre range and supports applications including extracellular vesicle research, viral vector analysis, and lipid nanoparticle characterisation. 

According to Bruker, the system provides size and concentration measurements within minutes and can even distinguish subpopulations in heterogeneous biological samples. A built-in well-plate reader is also intended to support standard laboratory workflows. 

Benchtop NMR and SPR systems target research and assay development. 

For chemistry laboratories, Bruker expanded its benchtop FT-NMR range with the Fourier 80 Automation Suite and the new Fourier 80 Duo. The company said these systems are designed and supported with 108 room-temperature positions, with options to 252 positions, plus optional cooling or heating, with barcode reading and user-defined waste handling to improve throughput, repeatability, and method standardisation in unattended batch workflows. 

It has highlighted the SPR Pro8 Series for biomolecular interaction analysis. The systems offer 24 or 32 measurement spots and up to eight buffer conditions per run to support assay development and multi-condition screening. 

A recent report by Towards Healthcare highlights that the Pre-Analytical Automation Market is witnessing growth due to the accelerating digital transformation initiative and the implementation of an interconnected automation platform to enhance operational efficiency, ensure sample integrity, reduce turnaround time, and improve overall laboratory efficiency. 

North America is the largest region, and Asia-Pacific is the fastest-growing region in the laboratory automation market, driven by rising investments in healthcare infrastructure, expanding pharmaceutical manufacturing, and the growing number of diagnostic laboratories in countries like China, India, and Japan. Governments in the Asia-Pacific are promoting automation to improve efficiency and quality in healthcare and clinical research.